explore -WSS

explore

author：focus 2025-09-03 07:52:39 - browse：58546

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

entertainment

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Vaccine advisory panel ACIP left half staffed by HHS

BioAge raises $170M for combination therapy with Zepbound

KalVista pill reduced swelling 'attacks' caused by genetic disease

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

Pope Francis asks Church to identify 21st

ChatGPT in medicine: STAT answers readers' burning questions

Princess Kate attends Wimbledon with Roger Federer: See the photos

Hollywood unions extend contract negotiations for actors

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Apple is now the first public company to be valued at $3 trillion

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

DIEP, the 'gold standard' of breast reconstruction, is under threat

Condition critical? Britain's beloved but battered National Health Service turns 75

Wikipedia

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare threatens to cut off funding for HCA's Mission hospital

Search warrant issued in 1996 disappearance of Kristin Smart

What should King Charles tell the public about his cancer?

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

leisure time

entertainment

explore

Wikipedia